2013 saw much progress in breast cancer research. Advances in high-throughput technologies continue to refine our knowledge of the molecular biology of breast cancer, and are beginning to give insight into cancer evolution, drug resistance, and how to deploy precision therapeutics.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339 (2013).
Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
Li, S. et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 4, 1116–1130 (2013).
Robinson, D. R. et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 45, 1446–1551 (2013).
Toy, W. et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 45, 1439–1445 (2013).
Murtaza, M. et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108–112 (2013).
Dawson, S. J. et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368, 1199–1209 (2013).
Davies, C. et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381, 805–816 (2013).
Pivot, X. et al. 6 Months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 14, 741–748 (2013).
Goldhirsch, A. et al. 2 Years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382, 1021–1028 (2013).
Acknowledgements
The work by the authors is supported in part by the National Cancer Institute of the NIH awards P30CA047904 (N. E. Davidson) and R01CA94118 (A. V. Lee). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The authors are also supported by funding through the Breast Cancer Research Foundation (N. E. Davidson and A. V. Lee), Susan G. Komen for the Cure (A. V. Lee), and the Pennsylvania Department of Health (N. E. Davidson and A. V. Lee). The Pennsylvania Department of Health specifically disclaims responsibility for any analyses, interpretations, or conclusions.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Lee, A., Davidson, N. Genomics, drug approval, and optimal treatment duration. Nat Rev Clin Oncol 11, 71–72 (2014). https://doi.org/10.1038/nrclinonc.2013.250
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2013.250
